EXOSURF NEONATAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EXOSURF NEONATAL (EXOSURF NEONATAL).
Exosurf Neonatal is a synthetic pulmonary surfactant containing dipalmitoylphosphatidylcholine (DPPC), cetyl alcohol, and tyloxapol. It reduces surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse and improving lung compliance and gas exchange.
| Metabolism | Not metabolized; composed of synthetic phospholipids and surfactants that are cleared via alveolar macrophage uptake and recycling. |
| Excretion | Primarily cleared from lungs via macrophage uptake and catabolism; minimal systemic absorption, thus negligible renal or biliary excretion (<1%). Exogenous surfactant components are recycled and re-secreted by type II pneumocytes. |
| Half-life | Not defined as terminal elimination half-life due to local pulmonary action. Clinical effect persists for 12–24 hours after a single dose, with surfactant pool turnover occurring over days. |
| Protein binding | Not applicable (local administration, minimal systemic absorption); surfactant phospholipids associate with endogenous surfactant proteins (SP-A, SP-B, SP-C) but standard protein binding is not measured. |
| Volume of Distribution | Not applicable for Vd (L/kg) as drug acts locally; negligible systemic distribution. Estimated alveolar fluid volume of ~10–20 mL/kg in neonates. |
| Bioavailability | Intratracheal: Essentially 100% direct delivery to alveoli; no first-pass metabolism. Oral or parenteral routes: Not applicable (0% bioavailability as intended for intratracheal use only). |
| Onset of Action | Intratracheal: Rapid, within minutes to 1 hour; improvement in oxygenation (PaO₂/FiO₂ ratio) observed as early as 15–30 minutes post-dose. |
| Duration of Action | Single dose provides clinical improvement for 12–24 hours; may require repeat dosing every 12 hours up to 3 doses total, with sustained effect over 48–72 hours in responders. |
Not applicable; Exosurf Neonatal is an endotracheal surfactant preparation indicated only for neonatal respiratory distress syndrome. No adult dosing exists.
| Dosage form | FOR SUSPENSION |
| Renal impairment | No adjustment necessary; the drug is administered locally to the lungs and is not absorbed systemically. |
| Liver impairment | No adjustment necessary; the drug is administered locally to the lungs and is not absorbed systemically. |
| Pediatric use | 5 mL/kg of the reconstituted suspension (containing 13.5 mg/mL phospholipids) intratracheally, divided into two half-doses, each instilled in a different lung position; may be repeated up to a total of 3 doses within 48 hours if persistent need. |
| Geriatric use | No geriatric indication exists; drug is not used in the elderly population. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EXOSURF NEONATAL (EXOSURF NEONATAL).
| Breastfeeding | No data on excretion of beractant into breast milk. Due to its high molecular weight and intra-tracheal route of administration, systemic absorption in the mother is minimal, making transfer into breast milk unlikely. M/P ratio unknown; considered compatible with breastfeeding if used for neonatal indication. |
| Teratogenic Risk | Exosurf Neonatal (beractant) is a synthetic pulmonary surfactant administered directly into the trachea of neonates. Systemic absorption is negligible; thus, no direct fetal risk exists from maternal use. No data on first trimester exposure; however, due to lack of systemic absorption, teratogenic risk is likely negligible in all trimesters. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to any component of Exosurf Neonatal.","Not indicated for term infants with RDS due to meconium aspiration or other causes."]
| Precautions | ["Rapid administration may cause transient bradycardia, hypotension, or oxygen desaturation.","Monitor for pulmonary hemorrhage, especially in very low birth weight infants.","May increase risk of intraventricular hemorrhage (IVH).","Use with caution in infants with patent ductus arteriosus (PDA)."] |
Loading safety data…
| Fetal Monitoring | During maternal administration (only for neonatal respiratory distress syndrome), monitor maternal vital signs, fetal heart rate, and uterine activity. After prophylactic or rescue treatment in neonate, monitor lung compliance, oxygenation, and chest X-ray. No specific maternal-fetal monitoring required for maternal use as drug is given to neonate. |
| Fertility Effects | No studies on human fertility. Given lack of systemic absorption, beractant is unlikely to affect female or male fertility. |